{"resourceType":"Task","id":"PGxRecEx02","meta":{"profile":["http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"]},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource \"PGxRecEx02\" </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-followup-recommendation.html\">Followup Recommendation</a></p></div><p><b>status</b>: requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: Consider alternative medication <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://loinc.org/\">LOINC</a>#LA26421-0)</span></p><p><b>description</b>: voriconazole - An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/.</p><p><b>for</b>: <a href=\"Patient-CGPatientExample01.html\">Patient/CGPatientExample01</a> \" EVERYMAN\"</p><p><b>reasonReference</b>: <a href=\"Observation-TxImp02.html\">Observation/TxImp02: Poor metabolizer</a></p></div>"},"status":"requested","intent":"proposal","code":{"coding":[{"system":"http://loinc.org","code":"LA26421-0","display":"Consider alternative medication"}]},"description":"voriconazole - An alternative agent that is not dependent on CYP2C19 metabolism such as isavuconazole, liposomal amphotericin B, or posaconazole is recommended as primary therapy in lieu of voriconazole. A lower than standard dosage of voriconazole with careful therapeutic drug monitoring is another alternative. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/.","for":{"reference":"Patient/CGPatientExample01"},"reasonReference":{"reference":"Observation/TxImp02","display":"Poor metabolizer"}}